Document:

France Telecom - Exhibit 10.1

Exhibit 10.1 

Consent of independent registered public accounting firm 

We consent to the incorporation by reference in Registration Statement No. 333-114841 on Form S-8 pertaining to the France Telecom Liquidity Plan for US Employees of Orange SA of our reports dated February 6, 2008, relating to the consolidated financial statements of France Telecom and subsidiaries, and on the effectiveness of France Telecom’s internal control over financial reporting, appearing in this Annual Report on Form 20-F of France Telecom for the year ended December 31, 2007.

/s/ DELOITTE & ASSOCIÉS 

Neuilly-sur-Seine, France 

May 2, 2008France Telecom - Exhibit 10.2

Exhibit 10.2 

Consent of independent registered public accounting firm 

We consent to the incorporation by reference in the Registration Statement (Form S-8 N°. 333-114841) pertaining to the France Telecom Liquidity Plan for US Employees of Orange SA of our reports dated February 6, 2008, with respect to the consolidated financial statements of France Telecom and the effectiveness of internal control over financial reporting of France Telecom, included in this Annual Report (Form 20-F) for the year ended December 31, 2007.

/s/ ERNST & YOUNG Audit 

Represented by Christian Chiarasini 

Paris - La Défense, France 

May 2, 2008exhibit4.htm

    Exhibit
4

     

     

     

    

    
      	
              

              For
      Immediate Release

            	
              

              News
      Release

            
	 
      	 
      
	 
      	 
      
	
              Endo
      Contact:

            	
              D.E.
      Shaw Contact:

            
	
              Charles
      A. Rowland, Jr.

            	
              Finsbury
      Group:

            
	
              610-558-9800

            	
              Andy
      Merrill / Tripp Kyle – New York

            
	 
      	
              andy.merrill@finsbury.com

            
	 
      	
              tripp.kyle@finsbury.com

            
	 
      	
              +1
      212 303 7600

            

    

    

    ENDO
PHARMACEUTICALS AND THE D.E. SHAW GROUP AGREE

    TO
SETTLEMENT

    

    CHADDS FORD, PA and NEW YORK, April
30, 2008 – Endo Pharmaceuticals Holdings, Inc. (NASDAQ: ENDP) and the
D. E. Shaw group, a global investment management firm, today announced
that

    they have
reached an agreement under which Endo’s Board of Directors will nominate William
F. Spengler at the 2008 Annual Meeting of Stockholders to serve as a member of
the Company’s Board of Directors.  The D. E. Shaw group,
which owns approximately 13.2 million shares of the Company’s common stock, has
agreed to vote all of its shares in favor of the election of each of the Board’s
nominees.  The Board of Directors is being increased to eight members,
effective June 26, 2008.  

    

    Mr.
Spengler, 53, was until February 2008 Executive Senior Vice President and Chief
Financial Officer at MGI Pharmaceuticals Inc., an oncology- and acute care-
focused bio-pharmaceutical company, where he had worked since 2005.  Prior
to joining MGI Pharma, Mr. Spengler was Executive Vice President and Chief
Financial Officer at Guilford Pharmaceuticals Inc. from July 2004 to October
2005.

    

    “I am
pleased that Bill Spengler will be joining the Endo board,” said Dave Holveck,
Endo's Chief Executive Officer.  “We look forward to his contribution
to Endo’s future growth.”

    

    “We are
confident that Bill Spengler will be a valuable addition to Endo’s Board of
Directors,” said Dr. James Mackey of the D. E. Shaw group.  “As
long-term shareholders, we look forward to maintaining a constructive dialogue
with Mr. Holveck and have been impressed by the initial steps he has taken to
position the company for growth and create value for shareholders.”

    

    As a
condition to the agreement, the D. E. Shaw group has agreed not to
solicit proxies from the Company’s stockholders in connection with the election
of directors or other matters until and, subject to certain other agreements,
through the Company’s 2009 Annual Meeting of Stockholders.  The Company’s
agreement with the D. E. Shaw group will be filed on a Form 8-K and
will be publicly available.

    

    About
Endo

    

    Endo
Pharmaceuticals Holdings Inc. is a specialty pharmaceutical company with market
leadership in pain management. Through its wholly owned Endo Pharmaceuticals
Inc. subsidiary, the company is engaged in the research, development, sale and
marketing of branded and generic prescription pharmaceuticals used primarily to
treat and manage pain. More information, including this and past press releases
of Endo Pharmaceuticals Holdings Inc., is available at
www.endo.com.

     

    About
the D. E. Shaw group

    

    The D. E.
Shaw group is a global investment and technology development firm with more than
1,300 employees; approximately $36 billion in aggregate investment capital as of
April 1, 2008; and offices in North America, Europe, and Asia. Since its
organization in 1988, the firm has earned an international reputation for
financial innovation, technological leadership, and an extraordinarily
distinguished staff.

    

     

    Forward-Looking
Statements

     

     

    This
press release contains information that includes or is based on “forward-looking
statements” within the meaning of Section 27A of the Securities Act of
1933, as amended, or the Securities Act, and Section 21E of the Securities
Exchange Act of 1934, as amended, or the Exchange Act. These statements,
including estimates of future net sales, future expenses, future net income and
future earnings per share, are subject to risks and uncertainties.
Forward-looking statements include the information concerning the company’s
possible or assumed results of operations. Also, statements including words such
as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “plan,” “will,”
“may” or similar expressions are forward-looking statements. Endo has based
these forward-looking statements on its current expectations and projections
about the growth of its business, its financial performance and the development
of its industry. Because these statements reflect Endo’s current views
concerning future events, these forward-looking statements involve risks and
uncertainties. Investors should note that many factors could affect Endo’s
future financial results and could cause its actual results to differ materially
from those expressed in forward-looking statements contained in this press
release. Important factors that could cause its actual results to differ
materially from the expectations reflected in the forward-looking statements in
this press release include, but are not limited to: its ability to successfully
develop, commercialize and market new products; timing and results of
pre-clinical or clinical trials on new products; its ability to obtain
regulatory approval of any of its pipeline products; competition for the
business of its branded and generic products, and in connection with its
acquisition of rights to intellectual property assets; market acceptance of its
future products; government regulation of the pharmaceutical industry; its
dependence on a small number of products; its dependence on outside
manufacturers for the manufacture of its products; its dependence on third
parties to supply raw materials and to provide services for certain core aspects
of its business; new regulatory action or lawsuits relating to its use of
narcotics in most of its core products; its exposure to product liability claims
and product recalls and the possibility that the company may not be able to
adequately insure itself; its ability to protect its proprietary technology; the
successful efforts of manufacturers of branded pharmaceuticals to use litigation
and legislative and regulatory efforts to limit the use of generics and certain
other products; its ability to successfully implement its acquisition and
in-licensing strategy; regulatory or other limits on the availability of
controlled substances that constitute the active ingredients of some of its
products and products in development; the availability of third-party
reimbursement for its products; the outcome of any pending or future litigation
or claims by the government; its dependence on sales to a limited number of
large pharmacy chains and wholesale drug distributors for a large portion of its
total net sales; significant litigation expenses to defend or assert patent
infringement claims; any interruption or failure by its suppliers, distributors
and collaboration partners to meet their obligations pursuant to various
agreements with Endo; a determination by a regulatory agency that Endo is
engaging in inappropriate sales or marketing activities, including promoting the
“off-label” use of its products; existing suppliers become unavailable or lose
their regulatory status as an approved source, causing an inability to obtain
required components, raw materials or products on a timely basis or at
commercially reasonable prices; the loss of branded product exclusivity periods
and related intellectual property; and its exposure to securities that are
subject to market risk.

     

     

    The
company does not undertake any obligation to update its forward-looking
statements after the date of this Report for any reason, even if new information
becomes available or other events occur in the future. You are advised, however,
to consult any further disclosures we make on related subjects in our 10-K, 10-Q
and 8-K reports to the Securities and Exchange Commission (or SEC). Also note
that Endo provides the preceding cautionary discussion of risks, uncertainties
and possibly inaccurate assumptions relevant to its business. These are factors
that, individually or in the aggregate, the company believes could cause its
actual results to differ materially from expected and historical results. Endo
notes these factors for investors as permitted by the Private Securities
Litigation Reform Act of 1995. You should understand that it is not possible to
predict or identify all such factors. Consequently, you should not consider the
preceding to be a complete discussion of all potential risks or
uncertainties.

    

     

    ###

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}]]